Achondroplasia dwarfism is the most common type of skeletal dysplasia. It’s the cause for 90% of cases of markedly short stature in people. Achondroplasia targets bone growth in the arms and legs.

Achondroplasia is a type of dwarfism that affects the growth in children, leading to a short stature or small size. Achondroplasia is a rare genetic condition that affects one in every 15,000 to ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia ...

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat people living with achondroplasia by providing continuous exposure of ...

Children of all ages with achondroplasia are now included in the expanded Indication, the most common form of skeletal dysplasia leading to disproportionate short stature. This article was ...

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of ...

The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found to be safe and effective at the highest studied dose among children with achondroplasia in a phase II dose-finding study.

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study. And ...

For more, go here. One study of children with achondroplasia found that 100 percent of them commando crawled when they first started crawling. As a parent, I didn’t know what to think.